Who are TRIAMTERENE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): olmesartan medoxomil-hydrochlorothiazide, Benicar, Zestril, Capozide 25/15, Enduron, Microzide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/triamterene.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

TRIAMTERENE — Competitive Intelligence Brief

TRIAMTERENE (TRIAMTERENE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazide Diuretic [EPC].

marketed Thiazide Diuretic [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

TRIAMTERENE (TRIAMTERENE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TRIAMTERENE TARGET	TRIAMTERENE		marketed	Thiazide Diuretic [EPC]		1964-01-01
olmesartan medoxomil-hydrochlorothiazide	OLMESARTAN	Cosette	marketed	Thiazide Diuretic [EPC]		2019-01-01
Benicar	OLMESARTAN MEDOXOMIL	Cosette	marketed	Thiazide Diuretic [EPC]	Type-1 angiotensin II receptor	2002-01-01
Zestril	lisinopril	Generic (originally Merck/AstraZeneca)	marketed	Thiazide Diuretic [EPC]	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1987-12-29
Capozide 25/15	CAPTOPRIL	Aarxion Anda Hlding	marketed	Thiazide Diuretic [EPC]	Renin	1981-01-01
Enduron	methylclothiazide		marketed	Thiazide Diuretic	Solute carrier family 12 member 3	1960-01-01
Microzide	hydrochlorothiazide	Generic (originally Merck)	marketed	Thiazide Diuretic [EPC]	ACE	1959-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-11-06 — Zestril · 12128083 · Formulation · US
2035-11-06 — Zestril · 9616096 · Method of Use · US
2035-11-06 — Zestril · 10039800 · Method of Use · US
2035-11-06 — Zestril · 10406199 · Method of Use · US
2035-11-06 — Zestril · 12433931 · Method of Use · US
2035-11-06 — Zestril · 10265370 · Formulation · US
2035-11-06 — Zestril · 9463183 · Formulation · US
2035-11-06 — Zestril · 11179434 · Formulation · US
2035-11-06 — Zestril · 9814751 · Formulation · US
2035-11-06 — Zestril · 10940177 · Formulation · US
2035-11-06 — Zestril · 11771733 · Formulation · US
2035-11-06 — Zestril · 12186360 · Formulation · US
2044-01-23 — Microzide · 11878022 · Formulation · US

Sponsor landscape (Thiazide Diuretic [EPC] class)

Cosette · 2 drugs in this class
Takeda · 2 drugs in this class
Daiichi Sankyo · 1 drug in this class
· 1 drug in this class
Generic (originally Merck) · 1 drug in this class
Generic (originally Merck/AstraZeneca) · 1 drug in this class
Roxane Laboratories · 1 drug in this class
Direct_Rx · 1 drug in this class
Aarxion Anda Hlding · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TRIAMTERENE — Competitive Intelligence Brief. https://druglandscape.com/ci/triamterene. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab